COVID-19 vaccines are not dangerous for the vast majority of people who receive them. Like all vaccines, they carry small risks of side effects, including rare but serious ones. But the evidence from hundreds of millions of doses consistently shows that the risks from vaccination are far smaller than the risks from a COVID-19 infection itself. Understanding exactly what those risks look like, and how rare they are, is the best way to make sense of the safety question.
Common Side Effects After Vaccination
Most people experience mild, short-lived reactions after a COVID-19 shot. Soreness at the injection site, fatigue, headache, muscle aches, chills, and low-grade fever are all normal immune responses that typically resolve within one to three days. These side effects tend to be more noticeable after the second dose of an mRNA vaccine than after the first. They are signs that your immune system is building protection, not signs of harm.
Severe Allergic Reactions
Anaphylaxis, a serious allergic reaction, occurs at a rate of roughly 11 cases per million doses of the Pfizer-BioNTech vaccine, based on early CDC monitoring data. Of those 21 initial confirmed cases, 17 involved people who already had a documented history of allergies, and seven had experienced anaphylaxis before. About 71% of reactions happened within 15 minutes of the shot, which is why vaccination sites ask you to wait and be observed afterward. Anaphylaxis is treatable with epinephrine, and nearly all reported cases resolved with prompt medical care.
Myocarditis Risk: Vaccine vs. Infection
Heart inflammation (myocarditis) drew significant attention as a rare side effect of mRNA vaccines, particularly in younger males after a second dose. The risk is real but needs context. A systematic review and meta-analysis published in Frontiers in Cardiovascular Medicine found that COVID-19 vaccination roughly doubled the baseline risk of myocarditis, while a COVID-19 infection increased that same risk by about 15 times. That translates to more than a sevenfold higher risk of myocarditis from the virus compared to the vaccine.
Most vaccine-associated myocarditis cases in young people have been mild, with symptoms like chest pain and fatigue that resolve within days to weeks. Myocarditis caused by the infection itself tends to be more severe.
Blood Clots and Adenovirus-Vector Vaccines
A rare clotting condition called vaccine-induced immune thrombotic thrombocytopenia (VITT) was linked to adenovirus-vector vaccines, including the AstraZeneca and Johnson &Johnson shots. In Norway, 5 cases of severe clotting with low platelet counts appeared among roughly 132,700 people who received the AstraZeneca vaccine. Four of those patients developed serious blood clots in the brain, and three died. The condition typically appeared 7 to 10 days after the first dose.
This risk was a major reason adenovirus-vector COVID-19 vaccines were pulled from use in many countries. The mRNA vaccines (Pfizer-BioNTech and Moderna) were not associated with VITT, and they are the only COVID-19 vaccines currently authorized in the United States.
Guillain-Barré Syndrome
Guillain-Barré syndrome (GBS), a nerve condition that can cause temporary weakness or paralysis, has a normal background rate of 1 to 2 cases per 100,000 people per year. A large study covering 15.1 million vaccine doses through the CDC’s Vaccine Safety Datalink found that the Johnson &Johnson vaccine was associated with a higher-than-expected GBS rate: about 32 cases per 100,000 person-years in the three weeks following vaccination. The mRNA vaccines showed a rate of 1.3 per 100,000 person-years in the same window, which was statistically indistinguishable from the normal background rate. This is another reason the Johnson &Johnson vaccine is no longer in use.
Autoimmune Conditions
Some people worry that COVID-19 vaccines could trigger autoimmune diseases. A large meta-analysis covering 97 million individuals found that COVID-19 infection itself raised the risk of new autoimmune conditions by 49%. The strongest links were with rare conditions like antiphospholipid syndrome, certain types of blood vessel inflammation, and immune-related platelet disorders. Crucially, the same analysis found that vaccinated individuals had a significantly lower risk of developing new autoimmune conditions after infection compared to unvaccinated individuals. The data suggest vaccination is protective against autoimmune complications, not a cause of them.
Pregnancy and Fertility
Concerns about fertility and pregnancy outcomes have been among the most persistent. A study comparing 300 vaccinated pregnant women to 104 unvaccinated pregnant women found no significant difference in stillbirth rates (2.0% vs. 1.0%, a gap that was not statistically meaningful). Babies born to vaccinated mothers were actually significantly less likely to have intrauterine growth restriction, a condition where the baby doesn’t grow properly in the womb (2.0% vs. 9.6%). Miscarriage rates were slightly higher in the vaccinated group (4.0% vs. 0%), though this single study’s findings sit within the range of normal miscarriage rates in the general population (10-20% of known pregnancies), and larger studies have not confirmed an increased risk.
What the Mortality Data Shows
A nationwide study in the Netherlands looked at all-cause deaths in the entire Dutch population and found that people were 44% less likely to die from any cause in the three weeks after primary vaccination compared to later periods. This pattern held across vaccine types, age groups, genders, and people with or without prior infection or other health conditions. The same study found that a positive COVID-19 test was associated with a 16-fold increase in the risk of dying in the following three weeks. These findings directly counter the claim that vaccines are driving excess deaths.
How Rare Side Effects Get Detected
The U.S. uses several overlapping systems to catch vaccine safety problems. VAERS (the Vaccine Adverse Event Reporting System) is an early warning system that accepts reports from anyone, including patients, parents, and healthcare workers. It is designed to spot unusual patterns, not to prove that a vaccine caused a specific event. When VAERS detects a signal, meaning an unusually high number of reports for a particular reaction, the CDC and FDA investigate using more rigorous databases that can determine whether a real risk exists. This layered approach is how the myocarditis signal in young men and the clotting risk from adenovirus vaccines were both identified and acted on within months of rollout.
The system is not perfect, but it is also not passive. Every serious safety concern that emerged with COVID-19 vaccines was caught by these monitoring tools, investigated, and in several cases led to vaccines being restricted or withdrawn.
Putting the Risks in Perspective
No vaccine is completely without risk. COVID-19 vaccines can cause rare serious side effects, and those risks are worth knowing about. But the data from billions of administered doses paints a consistent picture: the serious risks from vaccination are far less common and generally less severe than the risks posed by COVID-19 infection itself. Heart inflammation is more than seven times more likely after infection than after vaccination. Autoimmune conditions are significantly more likely after unvaccinated infection. And all-cause mortality data shows vaccinated people dying at lower rates, not higher ones. The vaccines that posed the greatest risks, specifically the adenovirus-vector shots, are no longer in use in most countries.